IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
The antitumor effects of therapeutic mAbs may depend on immune effector cells that express FcRs for IgG. IL-12 is a cytokine that stimulates IFN-γ production from NK cells and T cells. We hypothesized that coadministration of IL-12 with a murine anti-HER2/neu mAb (4D5) would enhance the FcR-dependent immune mechanisms that contribute to its antitumor activity. Thrice-weekly therapy with IL-12 (1 μg) and 4D5 (1 mg/kg) significantly suppressed the growth of a murine colon adenocarcinoma that was engineered to express human HER2 (CT-26(HER2/neu)) in BALB/c mice compared with the result of therapy with IL-12, 4D5, or PBS alone. Combination therapy was associated with increased circulating levels of IFN-γ, monokine induced by IFN-γ, and RANTES. Experiments with IFN-γ-deficient mice demonstrated that this cytokine was necessary for the observed antitumor effects of therapy with IL-12 plus 4D5. Immune cell depletion experiments showed that NK cells (but not CD4(+) or CD8(+) T cells) mediated the antitumor effects of this treatment combination. Therapy of HER2/neu-positive tumors with trastuzumab plus IL-12 induced tumor necrosis but did not affect tumor proliferation, apoptosis, vascularity, or lymphocyte infiltration. In vitro experiments with CT-26(HER2/neu) tumor cells revealed that IFN-γ induced an intracellular signal but did not inhibit cellular proliferation or induce apoptosis. Taken together, these data suggest that tumor regression in response to trastuzumab plus IL-12 is mediated through NK cell IFN-γ production and provide a rationale for the coadministration of NK cell-activating cytokines with therapeutic mAbs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, the therapeutic activity of these mAbs correlates with the abundance of NK cells, is influenced by genetic polymorphisms affecting Fc g R functions, and can be boosted (at least preclinically) by immunotherapeutic interventions preventing NK dysfunction (e.g., IL2 or IL12 administration) (Gennari et al., 2004; Jaime-Ramirez et al., 2011; Klein et al., 2017; Kono et al., 2002; Musolino”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Jaime-Ramirez et al., 2011
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“effector cells that bear FcgRs, such as NK cells (12, 13).”
BackgroundBaselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“(31) showed that in trastuzumab-treated”
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Chin, Y. E., Kitagawa, M., Su, W.-C. S., You, Z.-H., Iwamoto, Y., & Fu, X.-Y. (1996) · Science · doi:10.1126/science.272.5262.719 · Cited by 696
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Cited by
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
Self-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Metadata
- Authors
- Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., Biller, E., Lehman, A., Ray Chaudhury, A., Jarjoura, D., Burry, R. W., & Carson, W. E.
- Affiliations
- Integrated Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University , Columbus, OH 43210
- The Ohio State University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Breast Cancer Center, Memorial Cancer Institute , Pembroke Pines, FL 33028
- Cleveland Clinic (US)
- Department of Pathology, The Ohio State University , Columbus, OH 43210
- Corresponding author
- Biller, Elizabeth
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03
- Volume
- 186
- Issue
- 6
- Pages
- 3401-3409
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3593307
- OpenAlex
- W1924088703
- Cited by
- 100
- References
- 42
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 10 · 2019: 4 · 2018: 4 · 2017: 12 · 2016: 9 · 2015: 6 · 2014: 10 · 2013: 8 · 2012: 8
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ohio State University (CA16058, P30 CA16058)
- National Institutes of Health (T32 CA90338-27, CA‐16058, CA95426)
- National Cancer Institute (P01CA095426, K24CA093670, T32 CA90338-27, R21CA092286, P30CA016058)
- National Institute of General Medical Sciences (T32GM068412)
- National Center for Research Resources (UL1RR025755, K01RR022198)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- IL-12, trastuzumab, HER2/neu, natural killer cells, interferon-gamma, colon adenocarcinoma, RANTES, tumor regression, NK cell activation
- MeSH terms
- Trastuzumab, Adenocarcinoma, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Colonic Neoplasms, Cytotoxicity Tests, Immunologic, Female, Interferon-gamma, Killer Cells, Natural, Mice, Inbred BALB C, Random Allocation, Up-Regulation, Interleukin-12, Erb-b2 Receptor Tyrosine Kinases, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.